The Novo Nordisk Foundation pledged up to DKK 5.5 billion (about €736 million) to expand the BioInnovation Institute (BII), scaling its support from Danish startups to a Europe‑wide innovation engine. The commitment will double BII’s annual startup intake and extend partnerships across Europe to attract investors, industry partners and accelerate translational projects. BII and foundation statements framed the funding as targeted to close the gap from research excellence to commercial translation, supporting company formation, infrastructure and investor pipelines across biotech and med‑tech sectors.